Biotech nearly triples as mRNA cancer treatment shows promise after company had struggled in recent years

Moderna shares surged after positive Phase 3 results for its Merck-partnered melanoma cancer vaccine, boosting confidence in its portfolio beyond Covid-19.

The results come at a pivotal moment for Moderna and mRNA research.